{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:52:59Z","timestamp":1793087579993,"version":"4.5.0"},"reference-count":41,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.3201\/eid2906.221685","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T17:45:19Z","timestamp":1684259119000},"source":"Crossref","is-referenced-by-count":25,"title":["Association of Persistent Symptoms after Lyme Neuroborreliosis and Increased Levels of Interferon-\u03b1 in Blood"],"prefix":"10.3201","volume":"29","author":[{"given":"Sergio A.","family":"Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Ogrinc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi\u0161a","family":"Korva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Kastrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Bogovi\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Rojko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith W.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis J.","family":"Weis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franc","family":"Strle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemen","family":"Strle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid2906.221685-202305101105-R1","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3201\/eid2702.202731","article-title":"Estimating the frequency of Lyme disease diagnoses, United States, 2010\u20122018.","volume":"27","author":"Kugeler","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid2906.221685-202305101105-R2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000213069","article-title":"Epidemiology of lyme borreliosis.","volume":"37","author":"Hub\u00e1lek","year":"2009","journal-title":"Curr Probl Dermatol"},{"key":"key-10.3201\/eid2906.221685-202305101105-R3","first-page":"74","article-title":"An estimate of Lyme borreliosis incidence in Western Europe.","volume":"39","author":"Sykes","year":"2017","journal-title":"J Public Health (Oxf)"},{"key":"key-10.3201\/eid2906.221685-202305101105-R4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(11)60103-7","article-title":"Lyme borreliosis.","volume":"379","author":"Stanek","year":"2012","journal-title":"Lancet"},{"key":"key-10.3201\/eid2906.221685-202305101105-R5","doi-asserted-by":"publisher","first-page":"16090","DOI":"10.1038\/nrdp.2016.90","article-title":"Lyme borreliosis.","volume":"2","author":"Steere","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"key-10.3201\/eid2906.221685-202305101105-R6","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nrneurol.2015.121","article-title":"Lyme neuroborreliosis-epidemiology, diagnosis and management.","volume":"11","author":"Koedel","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"key-10.3201\/eid2906.221685-202305101105-R7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.idc.2015.02.012","article-title":"Posttreatment Lyme disease syndrome.","volume":"29","author":"Aucott","year":"2015","journal-title":"Infect Dis Clin North Am"},{"key":"key-10.3201\/eid2906.221685-202305101105-R8","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1172\/JCI138062","article-title":"Posttreatment Lyme disease syndromes: distinct pathogenesis caused by maladaptive host responses.","volume":"130","author":"Steere","year":"2020","journal-title":"J Clin Invest"},{"key":"key-10.3201\/eid2906.221685-202305101105-R9","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1056\/NEJMra072023","article-title":"A critical appraisal of \u201cchronic Lyme disease\u201d.","volume":"357","author":"Feder","year":"2007","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2906.221685-202305101105-R10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/cid\/cis402","article-title":"Treatment of erythema migrans with doxycycline for 10 days versus 15 days.","volume":"55","author":"Stupica","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2906.221685-202305101105-R11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1089\/vbz.2010.0018","article-title":"Comparison of post-Lyme Borreliosis symptoms in erythema migrans patients with positive and negative Borrelia burgdorferi sensu lato skin culture.","volume":"11","author":"Stupica","year":"2011","journal-title":"Vector Borne Zoonotic Dis"},{"key":"key-10.3201\/eid2906.221685-202305101105-R12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/cid\/ciw299","article-title":"Course and outcome of early European Lyme neuroborreliosis (Bannwarth syndrome): clinical and laboratory findings.","volume":"63","author":"Ogrinc","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2906.221685-202305101105-R13","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1086\/508667","article-title":"The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.","volume":"43","author":"Wormser","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2906.221685-202305101105-R14","doi-asserted-by":"crossref","unstructured":"Mygland A, Ljostad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I,  EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol. 2010;17:8\u201316, e1\u20134.","DOI":"10.1111\/j.1468-1331.2009.02862.x"},{"key":"key-10.3201\/eid2906.221685-202305101105-R15","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3390\/jcm7120506","article-title":"Clinical course, serologic response, and long-term outcome in elderly patients with early Lyme borreliosis.","volume":"7","author":"Bor\u0161i\u010d","year":"2018","journal-title":"J Clin Med"},{"key":"key-10.3201\/eid2906.221685-202305101105-R16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1093\/cid\/cit939","article-title":"Xenodiagnosis to detect Borrelia burgdorferi infection: a first-in-human study.","volume":"58","author":"Marques","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2906.221685-202305101105-R17","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1212\/01.WNL.0000284604.61160.2d","article-title":"A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy.","volume":"70","author":"Fallon","year":"2008","journal-title":"Neurology"},{"key":"key-10.3201\/eid2906.221685-202305101105-R18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJM200107123450202","article-title":"Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease.","volume":"345","author":"Klempner","year":"2001","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2906.221685-202305101105-R19","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1212\/01.WNL.0000071227.23769.9E","article-title":"Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial.","volume":"60","author":"Krupp","year":"2003","journal-title":"Neurology"},{"key":"key-10.3201\/eid2906.221685-202305101105-R20","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa1505425","article-title":"Randomized trial of longer-term therapy for symptoms attributed to Lyme disease.","volume":"374","author":"Berende","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2906.221685-202305101105-R21","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1128\/CVI.00071-16","article-title":"CCL19 as a chemokine risk factor for posttreatment Lyme disease syndrome: a prospective clinical cohort study.","volume":"23","author":"Aucott","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"key-10.3201\/eid2906.221685-202305101105-R22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jneuroim.2012.10.011","article-title":"Increased IFN\u03b1 activity and differential antibody response in patients with a history of Lyme disease and persistent cognitive deficits.","volume":"255","author":"Jacek","year":"2013","journal-title":"J Neuroimmunol"},{"key":"key-10.3201\/eid2906.221685-202305101105-R23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41584-021-00648-5","article-title":"Lyme arthritis: linking infection, inflammation and autoimmunity.","volume":"17","author":"Lochhead","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"key-10.3201\/eid2906.221685-202305101105-R24","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/cid\/cit735","article-title":"Elevated levels of IL-23 in a subset of patients with post-lyme disease symptoms following erythema migrans.","volume":"58","author":"Strle","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2906.221685-202305101105-R25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0022-510X(00)00501-3","article-title":"Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs.","volume":"184","author":"Reiber","year":"2001","journal-title":"J Neurol Sci"},{"key":"key-10.3201\/eid2906.221685-202305101105-R26","first-page":"544","article-title":"Characterization of Borrelia burgdorferi sensu lato strains isolated from human material in Slovenia.","volume":"114","author":"Ruzi\u0107-Sablji\u0107","year":"2002","journal-title":"Wien Klin Wochenschr"},{"key":"key-10.3201\/eid2906.221685-202305101105-R27","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/bmj.38933.585764.AE","article-title":"Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study.","volume":"333","author":"Hickie","year":"2006","journal-title":"BMJ"},{"key":"key-10.3201\/eid2906.221685-202305101105-R28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jama.2020.12603","article-title":"Persistent symptoms in patients after acute COVID-19.","volume":"324","author":"Carf\u00ec","year":"2020","journal-title":"JAMA"},{"key":"key-10.3201\/eid2906.221685-202305101105-R29","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1172\/JCI58813","article-title":"Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy.","volume":"122","author":"Bockenstedt","year":"2012","journal-title":"J Clin Invest"},{"key":"key-10.3201\/eid2906.221685-202305101105-R30","doi-asserted-by":"publisher","first-page":"13498","DOI":"10.1073\/pnas.1904170116","article-title":"Borrelia burgdorferi peptidoglycan is a persistent antigen in patients with Lyme arthritis.","volume":"116","author":"Jutras","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.3201\/eid2906.221685-202305101105-R31","doi-asserted-by":"publisher","first-page":"e2342","DOI":"10.1093\/cid\/ciaa1455","article-title":"Metabolic response in patients with post-treatment Lyme disease symptoms\/syndrome.","volume":"73","author":"Fitzgerald","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2906.221685-202305101105-R32","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/art.30384","article-title":"Burden and viability of Borrelia burgdorferi in skin and joints of patients with erythema migrans or lyme arthritis.","volume":"63","author":"Li","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key-10.3201\/eid2906.221685-202305101105-R33","doi-asserted-by":"publisher","first-page":"e1010365","DOI":"10.1371\/journal.ppat.1010365","article-title":"The Cdkn2a gene product p19 alternative reading frame (p19ARF) is a critical regulator of IFN\u03b2-mediated Lyme arthritis.","volume":"18","author":"Li","year":"2022","journal-title":"PLoS Pathog"},{"key":"key-10.3201\/eid2906.221685-202305101105-R34","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1002\/art.34383","article-title":"Association of a Toll-like receptor 1 polymorphism with heightened Th1 inflammatory responses and antibiotic-refractory Lyme arthritis.","volume":"64","author":"Strle","year":"2012","journal-title":"Arthritis Rheum"},{"key":"key-10.3201\/eid2906.221685-202305101105-R35","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.4049\/jimmunol.1701011","article-title":"Genetic control of Lyme arthritis by Borrelia burgdorferi arthritis-associated locus 1 is dependent on localized differential production of IFN-\u03b2 and requires upregulation of myostatin.","volume":"199","author":"Paquette","year":"2017","journal-title":"J Immunol"},{"key":"key-10.3201\/eid2906.221685-202305101105-R36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12866-016-0644-4","article-title":"Borrelia burgdorferi induces a type I interferon response during early stages of disseminated infection in mice.","volume":"16","author":"Petzke","year":"2016","journal-title":"BMC Microbiol"},{"key":"key-10.3201\/eid2906.221685-202305101105-R37","doi-asserted-by":"publisher","first-page":"8492","DOI":"10.4049\/jimmunol.181.12.8492","article-title":"A critical role for type I IFN in arthritis development following Borrelia burgdorferi infection of mice.","volume":"181","author":"Miller","year":"2008","journal-title":"J Immunol"},{"key":"key-10.3201\/eid2906.221685-202305101105-R38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.idc.2015.02.004","article-title":"Diagnosis and treatment of Lyme arthritis.","volume":"29","author":"Arvikar","year":"2015","journal-title":"Infect Dis Clin North Am"},{"key":"key-10.3201\/eid2906.221685-202305101105-R39","article-title":"The type I interferonopathies: 10 years on.","author":"Crow","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"key-10.3201\/eid2906.221685-202305101105-R40","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11096-005-1319-7","article-title":"Side effects of interferon-alpha therapy.","volume":"27","author":"Sleijfer","year":"2005","journal-title":"Pharm World Sci"},{"key":"key-10.3201\/eid2906.221685-202305101105-R41","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.biopsych.2004.02.009","article-title":"Cytokines and psychopathology: lessons from interferon-alpha.","volume":"56","author":"Capuron","year":"2004","journal-title":"Biol Psychiatry"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/29\/6\/22-1685_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:59:23Z","timestamp":1732989563000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/29\/6\/22-1685_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"URL":"https:\/\/doi.org\/10.3201\/eid2906.221685","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}